Table 3.
List of studies investigating the performances of BTA tests in surveillance setting in patients with non-muscle invasive bladder cancer
| Marker | Author (year) reference | Study design | No. of patients | Sensitivity (%) | Specificity (%) | Other end points |
|---|---|---|---|---|---|---|
| BTA STAT | Sarosdy (1995) [25] | Cohort prospective/case–control (separate) | 499/564 | 40 | 96 | – |
| Ianari (1997) [87] | Cohort | 75 | 54 | 91 | – | |
| Leyh (1997) [88] | Cohort prospective | 164 | 54 | 92 | – | |
| Hargreave (1997) [89] | Cohort prospective | 272 | 58 | 86 | – | |
| Sarosdy (1997) [90] | Cohort retrospective/case–control (separate) | 220/550 | 67 | 29-95 | – | |
| Serretta (2000) [77] | Marker-comparison retrospective | 179 | 57 | 62 | PPV 40%, NPV 76.9% | |
| Giannopoulos (2001) | Marker-comparison prospective | 95 | 72 | – | – | |
| Sarosdy (2002) [91] | Cohort/case–control (separate) | 438 | 50 | – | – | |
| Lokeshwar (2002) [24] | Cohort prospective | 26 | 61 | 74 | PPV 88%, NPV 38% | |
| Raitanen (2008) | Cohort prospective | 501 | 56 | 86 | – | |
| Yafi (2015) [17] | Marker-comparison prospective | 109 | 61 | 78 | – | |
| Bell (2016) [18] | Marker-comparison prospective | 91 | – | – | No association with RFS or PFS | |
| BTA Trak | Gutierrez Banoz (1999) [92] | Cohort | 122 | 61 | 87 | – |
| Serretta (2000) | Marker-comparison retrospective | 179 | 62 | 79 | PPV 45.4%, NPV 88.4% | |
| Sarosdy (2002) [91] | Cohort/case–control (separate) | 438 | 50 | – | – | |
| Fernandez Gomez (2002) [93] | Cohort | Unknown (700 samples) | 62 | 68 | – | |
| Babjuk (2008) [22] | Cohort prospective | 88 | 54 | 84 | – | |
| Bell (2016) [18] | Marker-comparison prospective | 91 | – | – | No association with RFS or PFS |
PPV positive predictive value, NPV negative predictive value, RFS recurrence-free survival, PFS progression-free survival